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Abstract
Multiple myeloma is a hematological cancer that is considered incurable despite advances in treatment strategy during the
last decade. Therapies targeting single pathways are unlikely to succeed due to the heterogeneous nature of the
malignancy. Proliferating cell nuclear antigen (PCNA) is a multifunctional protein essential for DNA replication and repair
that is often overexpressed in cancer cells. Many proteins involved in the cellular stress response interact with PCNA
through the five amino acid sequence AlkB homologue 2 PCNA-interacting motif (APIM). Thus inhibiting PCNA’s protein
interactions may be a good strategy to target multiple pathways simultaneously. We initially found that overexpression of
peptides containing the APIM sequence increases the sensitivity of cancer cells to contemporary therapeutics. Here we have
designed a cell-penetrating APIM-containing peptide, ATX-101, that targets PCNA and show that it has anti-myeloma
activity. We found that ATX-101 induced apoptosis in multiple myeloma cell lines and primary cancer cells, while bone
marrow stromal cells and primary healthy lymphocytes were much less sensitive. ATX-101-induced apoptosis was caspase-
dependent and cell cycle phase-independent. ATX-101 also increased multiple myeloma cells’ sensitivity against melphalan,
a DNA damaging agent commonly used for treatment of multiple myeloma. In a xenograft mouse model, ATX-101 was well
tolerated and increased the anti-tumor activity of melphalan. Therefore, targeting PCNA by ATX-101 may be a novel strategy
in multiple myeloma treatment.
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Introduction
Multiple myeloma (MM) is a cancer with clonal proliferation of
malignant plasma cells that accounts for about 13% of hemato-
logical cancers. The malignant cells in early- and middle-stage
disease are found in the bone marrow, suggesting a dependency on
the bone marrow microenvironment [1]. The median survival has
increased for MM patients following the introduction of new
treatments such as bortezomib and thalidomide/lenalidomide [2].
Nevertheless, MM is considered to be an incurable disease with
high relapse frequencies and thus new treatments are urgently
needed. It has been suggested that therapy targeting single
pathways may have limited benefits because of the high
heterogeneity of MM [3].
Proliferating cell nuclear antigen (PCNA) is an essential protein
in DNA replication and associated processes such as chromatin
remodeling/epigenetics and DNA repair [4,5]. It is frequently
used as a marker of proliferation and it is often overexpressed in
cancer cells [6]. In line with this, increased PCNA expression has
been correlated with increased micro vessel density and disease
activity in MM bone marrow biopsies [7]. Until recently, PCNA
was regarded as a strictly nuclear protein; however, PCNA in the
cytosol of differentiated neutrophils has been reported to be
involved in apoptosis regulation [8]. Additionally, PCNA was
found to be an inhibitor of natural cytotoxicity receptor NKp44
and to promote immune evasion of cancer cells [9]. Furthermore,
proteomic analysis has suggested that PCNA is involved in
coordination of glycolysis via direct interactions with six glycolytic
enzymes in the cytoplasm [10]. Thus, PCNA likely has several
functions outside the nucleus and beyond DNA replication and
repair.
The functionality of PCNA in the cell depends on its ability to
bind and recruit other proteins. PCNA has more than 400
potential protein interaction partners where the interactions are
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mediated via the two known protein-interacting sequences, the
PCNA-interacting peptide (PIP)-box [11] and AlkB homologue 2
PCNA-interacting motif (APIM) (http://tare.medisin.ntnu.no/
pcna/index.php) [12]. We have previously found that overex-
pressing an APIM-containing peptide rendered cancer cells
hypersensitive against various chemotherapeutics. The molecular
mechanism for this effect has heretofore not been fully elucidated,
but is likely explained by the ability of the APIM-peptide to inhibit
the interaction between PCNA and several of the more than 200
proteins containing APIM including DNA repair proteins [12,13].
In general, many targeted therapies fail due to development of
resistant cancer cell clones or activation of redundant pathways
[14–16]. The use of several different agents successively or
simultaneously to overcome resistance is probably a good strategy
[16]. Targeting PCNA would fit well with such strategies due to its
vital role in regulation of cellular homeostasis. By targeting PCNA
with ATX-101, an APIM-containing cell-penetrating peptide, we
induced apoptosis in MM cell lines and primary cells, and
increased the sensitivity against the chemotherapeutic melphalan.
Moreover, ATX-101 improved the efficacy of melphalan in a
xenograft MM mouse model. Our data suggest that the effects of
ATX-101 are mediated via its interaction with PCNA, and are
therefore likely caused by inhibition of PCNA’s normal interaction
with partners involved in stress response regulation.
Materials and Methods
Expression Constructs
Cloning of the fluorescently tagged expression constructs CFP-
PCNA and hABH2 1-7-F4W-YFP (APIM-YFP) has been
described [12,17]. The PIP-YFP (RFC 1-24-YFP) construct was
a kind gift from Dr. Emma Warbrick, University of Dundee, UK.
Site-directed mutagenesis of the PCNA construct was done
according to the manufacturer’s manual (QuikChange, Agilent
Technologies, Santa Clara, CA, USA).
Cell Penetrating Peptides
We ordered a series of peptides containing: the APIM consensus
(R/K- F/W/Y- L/I/V/A- L/I/V/A- K/R) [12] - a linker of 1-4
amino acids- a SV40 NLS (KKKRK)- a linker of 1-4 amino acids-
Figure 1. ATX-101, a cell-penetrating APIM-peptide, targets PCNA. (A) Confocal fluorescence image of live HeLa cells 2 minutes after
addition of fluorescently tagged ATX-101. Bar, 5 mm. (B) Cell growth measured by MTT assay of HeLa cells stably expressing YFP and APIM-(hABH2 1–7
F4W)-YFP unexposed (¤ and6, respectively) and after continuous exposure to 0.5 mM cisplatin (m andN, respectively) (left panel) and parental HeLa
cells unexposed (¤) and after continuous exposure to 8 mM ATX-101 (6), 0.5 mM cisplatin (m), and combination of ATX-101 and cisplatin (N) (right
panel). Data is from one representative experiment out of at least three. (C) Normalized FRET (NFRET) measurements in HeLa cells between CFP-PCNA
and APIM-YFP without and in the presence of ATX-101. The cells were treated with 8 mM ATX-101 8 h after transient transfection and incubated for
16 h before the NFRET measurements. CFP/YFP (vectors only) was used as background control. Data is from three independent experiments (mean 6
SEM, n = 36–40). P-value was calculated by the unpaired Student’s t-test. (D) Cell growth measured by MTT assay of HeLa cells unexposed (¤) and
after continuous exposure to 8 mM ATX-A ( ), 8 mM ATX-101 (6), 0.5 mM cisplatin (m), and combination of ATX-A or ATX-101 and cisplatin (& andN, respectively). The confocal image shows fluorescently tagged ATX-A in HeLa cells as in (A). Bar, 5 mm. Data is from one representative experiment
out of three.
doi:10.1371/journal.pone.0070430.g001
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and three different cell-penetrating peptides: Hiv-TAT
(RKKRRQRRR), penetratin (RQKIWFQNRRMKWKK) and
R-rich (11 Arg residues) (Innovagen, Lund, Sweden). We tested a
selection of these peptides for import and localization in cells by
adding a fluorescent tag to the C-terminus (K(-Ahx-5-FAM)G).
The peptides were next tested for biological activity in cell
Figure 2. ATX-101 inhibits cell growth of cancer cell lines. (A) Cell growth after ATX-101 addition in different cell lines measured by MTT assay.
K562 (chronic myelogenous leukemia), CCRF-CEM (T-lymphoblast, acute lymphocytic leukemia), RPMI-8226 and JJN-3 (MM), HeLa (cervical cancer),
PC3 and DU145 (prostate cancer), H460 (non-small cell lung carcinoma), HCT116 (colorectal carcinoma), A549 (non-small cell lung carcinoma), U2OS
(osteosarcoma) and HaCaT (spontaneously immortalized keratinocyte) cells were left unexposed (¤) and exposed to 4, 6, 8, 10, and/or 12 mM of ATX-
101 (&, m, 6, , and N, respectively). (B and C) Cell growth measured by MTT assay of the MM cell lines RPMI-8226 and JJN-3, respectively,
unexposed (¤) and after continuous exposure to 6 or 4 mM of ATX-101 (6), 2 or 0.5 mM melphalan (m), and combination of ATX-101 and melphalan
(N). (A–C) Data is normalized to cell growth from untreated cells on day 1 and from one representative experiment out of at least three.
doi:10.1371/journal.pone.0070430.g002
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proliferation assays (MTT and colony forming assays). We added
an acetyl to the N-terminal M of the peptide in order to increase
the stability. An APIM-cell penetrating peptide comprising the
following sequence was selected as the lead candidate: Ac-
MDRWLVKWKKKRKIRRRRRRRRRRR and named ATX-
101. In the mutant version of ATX-101, ATX-A, W4 is changed
to A.
Cells. HeLa cells (cervical cancer, ATCC CCL-2) transiently
and stably expressing fluorescently tagged proteins were prepared
and cultured as described [12]. JJN-3, RPMI-8226, URVIN
(MM), and U937 (histiocytic lymphoma) cells were grown in
RPMI 1640 (Sigma-Aldrich, Schnelldorf, Germany) supplemented
with 10% FCS (heat-inactivated for RPMI-8226 and URVIN),
2 mM glutamine (Sigma-Aldrich), 2.5 mg/ml amphotericin B
(Sigma-Aldrich) and 100 mg/ml gentamicin (Invitrogen, Carlsbad,
CA, USA). KJON and VOLIN (MM) cells were maintained in 5%
and 10% heat-inactivated human serum (HS), respectively, (Blood
Bank, St. Olav’s University Hospital, Trondheim, Norway) in
RPMI 1640 and IL-6 (2 ng/mL). JJN-3 (ACC 541, German
Collection of Microorganisms and Cell Cultures, Braunschweig,
Germany) are a gift from J. Ball (University of Birmingham,
United Kingdom) and RPMI-8226 (ATCC CCL-155) and U937
(ATCC CRL-1593.2) are from American Type Culture Collection
(Manassas, VA, USA). URVIN, KJON, and VOLIN were
established in-house [18]. Peripheral blood lymphocytes were
isolated from A+ buffy coats (Blood Bank, St. Olav’s University
Hospital) by density gradient centrifugation (Lymphoprep; Axis-
Shield PoC, Oslo, Norway) and were maintained in RPMI 1640
supplemented with 2 mM glutamine, 100 mg/ml gentamicin and
5% heat-inactivated HS. All cells were cultured at 37uC in a
humidified atmosphere of 5% CO2.
Immunofluorescence
Cells were grown on poly-lysine coated glass bottom dishes and
were stained as described [13] using antibody against (a) PCNA
(PC10, Santa Cruz biotechnology Inc., Dallas, TX, USA) and
Alexa fluor 532 goat a-mouse (Invitrogen). The nuclei were
stained with DRAQ5 according to the manufacturer’s manual
(eBioscience, San Diego, CA, USA).
Confocal Imaging
Live HeLa cells were examined 16–24 h after transient
transfection (by Fugene HD or X-tremeGENE HP [Roche, Oslo,
Norway] according to the manufacturer’s recommendations) with
Figure 3. ATX-101 induces apoptosis in the MM cell line JJN-3. (A–C) Flow cytometric measurement of the apoptotic cell population by
annexin V-Pacific Blue labeling. (A) JJN-3 cells treated with 6 mM ATX-101 and 0.5 mM melphalan alone or combined were incubated for 1, 2, and 3
days. Control cells were left unexposed. (B and C) JJN-3 cells treated with 6 and 10 mM ATX-101 were incubated for 1, 2, and 4 h. In addition to
annexin V labeling, cells were stained with DRAQ5 for DNA profile. (C) The histograms show the cell cycle distribution of live (blue) and apoptotic
(pink) cells after 1 h of ATX-101 treatments. (A–C) show data from representative experiments out of three. (D) Flow cytometric measurement of
caspase 8, 9, and 3/7 activity by Fluorescent Labeled Inhibitor of Caspases (FLICA) assay. JJN-3 cells were left unexposed and exposed to 8 mM ATX-
101 for 2 and 4 h before the FLICA probe was added for staining. The FLICA probe binds irreversible only to the activated caspase and labels
apoptotic cells. Data is from four independent experiments for caspase 8 activity and three independent experiments for caspase 9 and 3/7 activity
(mean 6 SD, ** P , 0.01, Student’s t-test).
doi:10.1371/journal.pone.0070430.g003
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the CFP/YFP fusion constructs. The fluorescent images were
acquired using a Zeiss LSM 510 Meta laser scanning microscope
equipped with a Plan-Apochromate 636/1.4 oil immersion
objective in the growth medium of the cell, with the stage heated
to 37uC, using the Zeiss LSM 510 software. CFP was excited at
l= 458 nm and detected at l= 470–500 nm and YFP was excited
at l= 514 nm and detected at l= 530–600 nm or l.560 nm.
The fluorescently labeled ATX-101 and ATX-A were excited at
l= 488 nm and detected at l= 505–530 nm in living HeLa cells
directly after addition in serum-free growth medium. The
immunofluorescently stained cells were excited at l= 543 nm
and detected at l.= 560–615 nm in 2% FCS in PBS at RT.
Figure 4. MM cell lines have PCNA in their cytosol. (A) Confocal fluorescence images of immunofluorescently stained PCNA (green) in JJN-3,
RPMI-8226 cells and three new in-house made MM cell lines (KJON, VOLIN, and URVIN). DRAQ5 was used for nuclear staining (blue) of KJON, VOLIN,
and URVIN. HeLa cells were used as control for low levels of PCNA staining in the cytosol (fluorescence image of PCNA and transmitted light image).
Bar, 5 mm. (B) Western blot analysis of caspase 3 cleavage (Input, upper panel) and co-immunoprecipitation of procaspase 3 using a-PCNA beads (IP
PCNA, lower panel) from JJN-3 cells after overnight treatment with 6 and 10 mM ATX-101 alone or in combination with 1 mM melphalan. The bar
graphs show the quantification from the blot above. Cleaved caspase 3 in the input samples (upper panel) was corrected for loading differences (b-
actin) and normalized to procaspase 3. (C) Western blot analysis of caspase 3 and caspase 8 cleavage in RPMI-8226 cells after 4 h treatment with 6
and 10 mM ATX-101 alone or in combination with 2 mM melphalan. The bar graphs show the quantification of cleaved caspase 3 normalized to
procaspase 3 after correction for loading differences (b-actin) (upper graph) and cleaved caspase 8 normalized to b-actin (lower graph). (B and C)
show results from representative experiments out of at least three.
doi:10.1371/journal.pone.0070430.g004
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DRAQ5 was excited at l= 633 nm and detected at l.650 nm.
The thickness of the slice was 1 mm. All images were acquired with
consecutive scans to avoid bleed through. No image processing,
except contrast and intensity adjustments, were performed.
Fluorescence Resonance Energy Transfer (FRET) Analysis
FRET occurs if tags with spectral overlap (here: CFP and YFP)
are less than 100 A˚ (10 nm) apart [19]. We detected FRET using
the sensitized emission method, measuring acceptor (YFP)
emission upon donor (CFP) excitation. FRET was scored when
the intensity of emitted light from YFP after excitation of the CFP
fluorochrome was stronger than the light emitted by CFP or YFP-
tagged proteins alone, after excitation with the CFP laser (false
FRET), given by the equation: FRET = I2–I1 (ID2/ID1) - I3
(IA2/IA3). I is mean intensity detected in the 3 different channels.
ID1, D2, D3 and IA1, A2, A3 were determined for cells
transfected with CFP and YFP constructs only, with same settings
and same fluorescence intensities as co-transfected cells (I1, I2, I3).
FRET.0 was normalized for expression levels using the equation:
NFRET = FRET/(I16I3)1/2 [20,21]. NFRET was calculated from
mean intensities within a region of interest representing replication
foci containing more than 25 pixels where all pixels had intensities
below 250. Channel 1 (CFP) and 3 (YFP) were measured as
described for confocal imaging, and channel 2 (FRET) was excited
with l= 458 nm and detected at l= 530–600 nm or l.560 nm.
Flow Cytometry
Cells were treated with different doses of ATX-101 alone and in
combination with melphalan and were collected after the
indicated time of continuous exposure. For measurement of the
apoptotic cell population, the cells were stained with annexin V-
Pacific Blue (Invitrogen) and propidium iodide to stain for dead
cells, when noted, according to the manufacturer’s instructions.
For cell cycle phase analysis cells were additionally stained with
DRAQ5. Specific caspase activity was detected by FLICA Caspase
Assay Kits (Immunochemistry Technologies LLC, Bloomington,
MN, USA). All cells were analyzed by a FACSAria and the
FACSDiva software (BD Biosciences, San Jose, CA, USA).
Preparation of Cell Extract and Western Analysis
JJN-3 cells were seeded at 350 000 cells/ml and treated with
ATX-101/melphalan overnight as indicated. RPMI-8226 cells
were seeded and treated as JJN-3 for only 4 h. The cells were
harvested and the pellet was resuspended in buffer 1 (10 mM Tris-
HCl pH 8.0, 200 mM KCl, 1 mM DTT, 10 ml/ml Phosphatase
Inhibitor Cocktail [PIC 1 and 2, Sigma-Aldrich] and 16Complete
Protease Inhibitor [Roche]). The same volume of buffer 2 (10 mM
Tris-HCl pH 8.0, 200 mM KCL, 2 mM EDTA, 40% glycerol,
0.5% NP40, 1 mM DTT, 10 ml/ml PIC 1 and 2 and 16Complete
Protease Inhibitor) was added and incubated for 1.5 h at 4uC on a
roller shaker. The cell extracts were centrifuged and separated on
4–12% Bis-Tris-HCl (NuPAGE, Invitrogen) gels. Proteins were
detected by western blot as described [12] using a-caspase 3
(9662), a-cleaved caspase 8 (9748, Cell Signaling, Beverly, MA,
USA), and a-beta-actin (Abcam, Cambridge, UK) as loading
control.
Immunoprecipitation
1 000 mg cell extract from JJN-3 cells were incubated with 5 ml
a-PCNA-coupled beads (Abcam 18197) under constant rotation at
4uC overnight. The beads were washed 3 times with buffer 1,
resuspended in LDS loading buffer (NuPAGE, Invitrogen) and
1 mM DTT and heated for 15 min at 70uC. Elutions were
analyzed by western blot.
Cell Survival Assay
Cells were seeded into 96-well plates and different doses of
ATX-101 and chemotherapeutic drugs were added. Cells were
exposed continuously and harvested every day for the next four
days using the MTT (3-(4.5-Dimethylthiazol-2-yl)-2.5 diphenyl-
tetrazolium bromide) assay as described [12]. The average from at
least 4 wells was used to calculate cell survival.
Primary Myeloma Cells
Fresh CD138 positive myeloma cells were isolated from bone
marrow samples obtained from the Norwegian Myeloma Biobank
using RoboSep automated cell separator and Human CD138
Positive Selection Kit (StemCell Technologies, Grenoble, France).
The patient myeloma cells were grown in RPMI medium
supplemented with 2% heat-inactivated HS and melphalan/
ATX-101 as indicated. Cell viability was measured after 3 days
using annexin V-FITC and propidium iodide staining (as
described for Flow cytometry). All samples were run in duplicate.
Bone marrow stromal cells (BMSC) were made by seeding the
remaining mononuclear cells from the CD138 positive selection in
culture flasks. The cells were grown in RPMI with 10% HS. After
Figure 5. APIM and PIP-box peptides have overlapping binding site on PCNA. (A) Protein sequence and structural model of PCNA (PDB
entry 1vym) with M40 highlighted in red and the center loop (CL) in yellow (upper panel). Live cell (HeLa) confocal fluorescence images of CFP-PCNA
wild type (WT) and CFP-PCNA M40 mutants. Bar, 5 mm (lower panel). (B) Normalized FRET (NFRET) measurements between WT and mutated CFP-PCNA
M40/APIM-YFP (light grey diamonds, PCNA WT2/PCNA M40A2/PCNA M40N2/PCNA M40R2/PCNA M40S- APIM) and WT and mutated CFP-PCNA
M40/PIP-YFP (dark grey diamonds, PCNA WT2/PCNA M40A2/PCNA M40N2/PCNA M40R/PCNA M40S- PIP). CFP/YFP (vectors only) was used as
background control (open diamonds). Data is from three independent experiments (mean 6 SEM, n = 72–214). P-values were calculated by the
unpaired Student’s t-test.
doi:10.1371/journal.pone.0070430.g005
Figure 6. ATX-101 induces cancer cell specific apoptosis. Flow
cytometric measurement of the apoptotic cell population by annexin V-
Pacific Blue labeling. JJN-3 cells were treated with 4 and 8 mM ATX-101
for 2 h (left panel), and U937 cells were treated for 24 h (right panel).
Lymphocytes freshly isolated from buffy coats (from blood donors)
treated in parallel with JJN-3 and U937 are included as controls. Data is
from representative experiments out of two.
doi:10.1371/journal.pone.0070430.g006
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3 days of culture, cells in suspension were removed, and the
remaining adherent cells were expanded and split after about 10
days. After 3 weeks, cells from ten different patients were mixed to
obtain standardized BMSC for use in co-culture experiments with
myeloma cells.
Co-culture Experiments
BMSC (2 500 cells/well) were plated in 96-well plates and
allowed to adhere for ,3 h, before addition of primary myeloma
cells (5 000 cells/well). Drugs were added at the concentrations
indicated. The cells were cultivated in RPMI medium supple-
mented with 2% HS in a total volume of 200 ml/well. Experiments
Figure 7. ATX-101 induces apoptosis in primary MM cells and increases the efficacy of melphalan in vivo. (A) Flow cytometric
measurement of the viable cell population by annexin V-FITC and propidium iodide labeling of cancer cells isolated from seven MM patients (MM1–7)
after treatment with 6 mM ATX-101 and 1 mM melphalan alone or in combination for 3 days. Data is normalized to the viable cell population of
untreated patient cells after 3 days (100% viable cells). (B) Fluorescence microscopical measurement of the viable cell population by DRAQ5 and YO-
PRO-1 staining of cancer cells from seven MM patients (MM8–14) cultured alone and in presence of BMSC. The cells were treated with 2 and/or 4 mM
ATX-101 alone for 3 days (MM8-11). MM12 -14 were also treated with 1 mM melphalan alone and in combination with ATX-101. Data is normalized to
the viable cell population of untreated patient cells in presence of BMSC after 3 days (100% viable cells). (C) NOD/SCID mice bearing subcutaneous
RPMI-8226 tumors were treated with vehicle (&), 13.5 mg/kg ATX-101 (6), 3 mg/kg melphalan (m), and combination of ATX-101 and melphalan (N).
Tumor volume (left panel) and body weight changes (right panel) are shown as mean 6 SD (n = 10 mice/group). P-values were calculated by the
ANOVA test.
doi:10.1371/journal.pone.0070430.g007
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were also performed with primary myeloma cells alone. All
samples were run in duplicate. After 3 days incubation 1 mM YO-
PRO-1 (Invitrogen) were added to the wells and the plate was
incubated for 30 minutes at 37uC. 2.5 mM DRAQ5 were added to
the wells 15 minutes before fluorescence was measured at a ScanR
automated fluorescence microscope (Olympus, Hamburg, Ger-
many). Acquired images were analyzed using ScanR Image
Analysis software. Details on how the image acquisition and image
analysis were performed will be presented in a separate method
paper [22]. In brief, BMSC and myeloma cells were distinguished
and gated based on the staining intensity and area of their nucleus.
Viable cells were gated by a high intensity of DRAQ5 nuclear
staining and low YO-PRO-1 staining.
Mice Xenograft Study
Efficacy experiments using intra-peritoneal (i.p.) injections of
vehicle, ATX-101, melphalan or a combination of melphalan and
ATX-101 on subcutaneous RPMI-8226 human myeloma xeno-
grafts in NOD/SCID mice were performed by Crownbio
(Changping Sector of Zhongguancum Scientific Park, No.21
Huonju Road, Changping District, Beijing, China). Ten tumor-
bearing 8–9 weeks old NOD/SCID mice (22–28 g) in each group
were observed in a 3-week treatment efficacy study during a 29-
day in-life period after their mean tumor volume reached 129
mm3. Tumor volumes were measured twice per week in two
dimensions using a caliper, and the volume is given in mm3 using
the formula: V = 0.5 a6b2 where a and b are the long and short
diameters of the tumor, respectively. ATX-101 was given twice
daily for 3 weeks (Bid6763, i.p.) at a dose of 13.5 mg/kg per dose,
whereas melphalan was given once weekly for three weeks (i.p.) at
a dose of 3 mg/kg. Of note, the chronic maximum tolerated dose
i.p. of ATX-101 exceeds 25 mg/kg in SCID mice (unpublished
data).
Ethics Statement
The study on patient myeloma cells and the establishment of the
cell lines KJON, URVIN, and VOLIN were approved by the
Regional Committee for Medical and Health Research Ethics
Central Norway (REC Central, permit numbers: REK 2011/2029
and REK 4.2007.933) and the patients had given written informed
consent. The animal study was performed by Crownbio according
to international regulations. The protocol and any amendment(s)
or procedures involving the care and use of animals in this study
were reviewed and approved by the Institutional Animal Care and
Use Committee (IACUC) of Crownbio prior to conduct. During
the study, the care and use of animals was conducted in
accordance with the regulations of the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC).
Animals that were observed to be in a continuing deteriorating
condition or for which the tumor size exceeded 3000 mm3 were
euthanized prior to death, or before reaching a comatose state.
One animal (vehicle control group) was sacrificed on day 22.
Results
Design of ATX-101, a Cell-penetrating APIM-containing
Peptide Targeting PCNA
To identify peptides that could penetrate the cell membrane
and target PCNA throughout the cell, we constructed a series of
peptides containing the APIM consensus with a SV40 nuclear
localization signal and different cell-penetrating peptide domains.
We subsequently tested these peptides for cellular import and
biological activity and selected one lead candidate, ATX-101. A
fluorescently tagged version of ATX-101 showed that it was
rapidly imported into the cells, where it localized to the cytosol,
throughout the nucleoplasma, in nucleoli, and in small spots in the
nucleoplasma (Figure 1A). We found that addition of ATX-101 to
HeLa cells increased their sensitivity against the intra- and
interstrand crosslinker cisplatin similarly to intracellularly ex-
pressed APIM-YFP (Figure 1B). This is in accordance with
previous results for methyl methanesulfonate, carmustine, temo-
zolomide, and mitomycin C treated HeLa cells [12]. APIM-YFP
interacts directly with PCNA via the APIM sequence, and
mutation in the conserved aromatic amino acid 4 in APIM (F/
W/Y to A) abolished this interaction and the ability to sensitize
cells to chemotherapeutics [12]. Thus, we examined whether the
interaction between APIM-YFP and CFP-PCNA was affected by
ATX-101 addition by measuring fluorescence resonance energy
transfer (FRET) (Figure 1C). The addition of ATX-101 reduced
the FRET level measured between APIM-YFP and CFP-PCNA,
strongly indicating that ATX-101 impairs the APIM-PCNA
interaction. These results suggest that the APIM sequence in
ATX-101 is targeting PCNA because the only similarity between
ATX-101 and APIM-YFP is the APIM sequence. To further
support that PCNA is the cellular target of ATX-101, we designed
a mutant cell-penetrating peptide version of ATX-101, ATX-A, in
which only W4 in the APIM sequence of ATX-101 is substituted
with A. ATX-A was imported into HeLa cells similarly to ATX-
101, but it did not sensitize the cells to cisplatin (Figure 1D). This
suggests that the sensitizing effect of ATX-101 is caused by PCNA
targeting via the APIM sequence.
ATX-101 Inhibits Cell Growth and Potentiates the
Cytotoxicity of Melphalan in MM Cell Lines
Having established that ATX-101 is properly imported in HeLa
cells and targets PCNA, we sought to identify ATX-101 sensitive
cancer cell lines using proliferation assays. Different sensitivity
against ATX-101 was detected in the different cancer cell lines,
and hematological cancer cell lines were highly sensitive
(Figure 2A).
The MM cell lines RPMI-8226 and JJN-3 were sensitive to
ATX-101 either alone or in combination with melphalan, an
interstrand crosslinking drug frequently used in MM treatment
(Figures 2A–C). Furthermore, ATX-101 increased the sensitivity
of these MM cell lines against other chemotherapeutics such as
thalidomide, doxorubicin, vorinostat, azacitidine, and various
kinase inhibitors (unpublished data). Similar results were found in
the MM cell lines U266 and H929 (unpublished data).
ATX-101 Induces Rapid Apoptosis in MM Cell Lines
Next, we examined whether ATX-101 actively induced
apoptosis. We observed the apoptotic cell population of JJN-3
cells continuously exposed to ATX-101 and/or melphalan over 3
days by annexin-V staining. ATX-101 induced apoptosis as a
single agent in addition to increasing melphalan-induced apoptosis
(Figure 3A). Notably, ATX-101 and melphalan alone showed a
temporally different induction of apoptosis: the pro-apoptotic
effect of ATX-101 was most pronounced on day 1, whereas
melphalan increased the apoptotic cell population over time.
ATX-101 had an increasing effect on melphalan-induced apop-
tosis at all days. Furthermore, we found that apoptosis was induced
even 1 h after ATX-101 addition, and that apoptotic cells were
found in all phases of the cell cycle (Figures 3B and C). We
included propidium iodide controls for membrane permeability to
check whether the cell-penetrating properties of ATX-101
damaged the cell membrane leading to false positives. We found
no increase in propidium iodide uptake at these time points
(unpublished data).
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We next tested whether the rapid ATX-induced apoptosis was
mediated by caspases. ATX-101 induced caspase 8, 9 and 3/7
activation within 2 h as assessed by specific FLICA caspase assays
(Figure 3D). Thus, our results show that ATX-101 induces rapid
apoptosis via caspase-dependent mechanisms in MM cells.
APIM and PIP-box Peptides have Overlapping Binding
Sites on PCNA, Suggesting that Targeting PCNA with
ATX-101 Induces Caspase Cleavage by Inhibiting PCNA-
procaspase Interactions
Our mechanistic studies on ATX-101 (Figure 1) suggest that the
APIM sequence in ATX-101 targets PCNA. Interestingly, it has
been reported that PCNA is found in the cytosol of differentiated
neutrophils where it exerted an anti-apoptotic effect by directly
interacting with procaspase 3, 8, 9, and 10 [8]. Thus first, we
examined the PCNA content in different compartments in MM
cells. We tested RPMI-8226, JJN-3, and in-house prepared MM
cell lines (KJON, URVIN, and VOLIN). All cell lines contained
higher PCNA levels in the cytosol than HeLa cells (Figure 4A).
Next, we immunoprecipitated PCNA from JJN-3 cell extracts and
analyzed the precipitate for procaspase 3. We verified that
procaspase 3 co-immunoprecipitates with PCNA. Additionally,
we found that less procaspase 3 was co-immunoprecipitated in
cells treated with ATX-101 (Figure 4B, lower panel). We also
verified that ATX-101 treatment induced procaspase 3 and 8
cleavage by western analysis (Figures 4B and C), further
supporting a caspase-dependent apoptosis.
Witko-Sarsat and colleagues reported that a peptide containing
the PIP-box inhibited the interaction between PCNA and the
procaspases, and thereby induced apoptosis [8]. The rapid
apoptosis observed after ATX-101 addition may suggest that the
APIM-peptide has a similar mechanism of action. We therefore
examined whether the APIM sequence bound to the same site on
PCNA as the PIP-box. The interaction site of the PIP-box on
PCNA is known, and the PIP-box containing protein FEN-1 has
been co-crystallized with PCNA [23]. The PIP-box in FEN-1 is
embedded in a hydrophobic pocket in PCNA close to the center
loop (CL) (yellow in Figure 5A). In order to examine whether the
APIM-peptide used shared interaction site on PCNA with the PIP-
box, we selected one amino acid in this hydrophobic pocket of
PCNA for mutation (Met (M) 40 adjacent to CL). We mutated
M40 in PCNA to Ala (A), Asn (N), Ser (S), and Arg (R). The
intracellular localization of these mutated PCNAs was similar to
wild type PCNA, supporting functionality of the mutant proteins
(Figure 5A, lower panel). Thus, we were able to measure FRET
between the different mutated CFP-PCNAs and APIM-YFP, as
well as between CFP-PCNAs and PIP-YFP. A reduction in FRET
is observed when the interaction between APIM-PCNA or PIP-
PCNA is impaired by the mutation. We found that FRET between
both APIM-PCNA and PIP-PCNA were reduced when M40 was
mutated (Figure 5B). This suggests that both the APIM sequence
and the PIP-box interact with the hydrophobic pocket of PCNA.
Thus, a likely mechanism of action for ATX-101 in MM cells is
that it induces caspase-dependent apoptosis by inhibiting the
interaction of the procaspases with PCNA similarly to what is
reported for the PIP-peptide [8].
ATX-101 Induces Apoptosis in a Cancer Cell Specific
Manner
We found that hematological cancer cell lines were generally
more sensitive to ATX-101 as a single agent than other cancer cell
lines (Figure 2A). To examine the pro-apoptotic effect of ATX-101
on healthy hematological cells, we compared ATX-101-induced
apoptosis in JJN-3 and the leukemic monoblast cell line U937,
with lymphocytes from healthy donors. We found that the cancer
cell lines were more sensitive to ATX-101 than primary
lymphocytes and monocytes (Figure 6 and unpublished data,
respectively). These results indicate that ATX-101 induces
apoptosis preferentially in cancer cell lines.
ATX-101 Induces Apoptosis in MM Cells ex vivo
Unlike MM cell lines, primary MM cells rarely proliferate
in vitro. Thus, we examined the effect of ex vivo ATX-101 treatment
on primary MM cells both alone and in combination with
melphalan. We found that ATX-101 induced apoptosis as a single
agent, similar to what we observed in MM cell lines. Additionally,
we detected an increase in the efficacy of melphalan in
combination with ATX-101 in some cases (Figure 7A). In all of
the 19 patient samples tested (14 of which are displayed in
Figures 7A and B) an increase in apoptosis was observed after
addition of ATX-101 doses between 2–6 mM.
The bone marrow provides a protective microenvironment for
the MM cells, and resistance toward anti-cancer drugs can be
mediated through supportive stromal cells and/or extracellular
matrix in the bone marrow [24,25]. However, in our BMSC co-
culture apoptosis assay ATX-101 also efficiently induced apoptosis
in primary MM cells (Figure 7B). Under the conditions used in
these experiments less than 20% of apoptotic cells were detected in
the BMSC population (unpublished data), further supporting a
cancer cell specificity of ATX-101. The efficacy of ATX-101 is
comparable to melphalan and bortezomib at similar molar
concentration using this assay (Figure 7B and unpublished data,
respectively). These results suggest that the pro-apoptotic effect of
ATX-101 is not restricted to highly proliferating cancer cell lines
but can also be observed in ex vivo assays of patient-derived non- or
slowly proliferating MM cells.
ATX-101 Potentiates the Efficacy of Melphalan in a
Xenograft MM Mouse Model
To further corroborate our in vitro and ex vivo results, we sought
to establish the therapeutic effect of ATX-101 in an in vivo
xenograft MM mouse model. ATX-101 showed no significant
efficacy as a single agent, but it improved the efficacy of melphalan
significantly (Figure 7C). ATX-101 showed no toxic effects alone
or in combination with melphalan as measured by body weight
changes, suggesting that the treatment was well-tolerated
(Figure 7C). These results confirm our in vitro and ex vivo data,
and support the cancer cell specific action of ATX-101.
Discussion
In this study we have shown that the multifunctional protein
PCNA is a drug target of interest in MM treatment. The APIM-
comprising peptide ATX-101 is capable of inducing rapid
apoptosis as a single agent and increasing the cytotoxic effect of
melphalan in MM cell lines, primary cells, and a xenograft mouse
model. ATX-101 likely functions via several mechanisms because
many proteins involved in stress responses contain the APIM
sequence (http://tare.medisin.ntnu.no/pcna/index.php) and
ATX-101 could potentially inhibit any of their interactions with
PCNA.
Our data shows that ATX-101 induces rapid caspase-depen-
dent apoptosis (within 1 h) and also increases the efficacy of
melphalan up to four days after addition. This suggests that ATX-
101 acts along at least two different pathways in MM cells: a direct
and rapid apoptosis-inducing pathway and a more indirect
pathway that is possibly dependent upon a reduced ability to
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repair melphalan-induced DNA damage. The basis for the latter is
that DNA repair proteins involved in repair of melphalan-induced
DNA damage have verified functional APIM sequences
(RAD51B, topoisomerase II a, xeroderma pigmentosum group
A) [12,13]. In addition, ZRANB3, a central protein involved in
restarting arrested replication forks, has a functional APIM
sequence [26].
The rapid induction of apoptosis by ATX-101 could be
explained by an inhibition of the binding between cytosolic
PCNA and procaspases leading to direct caspase activation,
similar to what was found in neutrophils by Witko-Sarsat et al. [8];
however, ATX-101 did not induce apoptosis in normal lympho-
cytes, monocytes, or BMSC, although monocytes showed similar
cytosolic PCNA levels as MM cell lines (unpublished data). Thus,
there seems to be some specificity toward malignant cells.
Interestingly, we previously observed that the PCNA that was
immunoprecipitated with an APIM-peptide had a different
isoelectric distribution than the total PCNA in the cell, suggesting
that the PCNA interacting with APIM-peptides has specific post-
translational modifications [12]. The exact nature of these post-
translational modifications remains elusive. Several proteins
essential for replication contain the PIP-box (e.g. pol d, RFC,
FEN-1), while many proteins involved in stress related processes
contain the APIM sequence [5,12,26]. It has been demonstrated
that certain cancer cells are stressed as a consequence of their
genomic mutations, and it is thus possible that the total PCNA in
these cells contains more of a modified PCNA with high affinity for
APIM-peptides that could sensitize these cancer cells to ATX-101
treatment. In accordance with the apoptosis-inducing activity of
the PIP-box-peptide detected by Witko-Sarsat and colleagues [8],
all attempts to make stable U2OS cells overexpressing a PIP-box-
peptide fused to YFP were unsuccessful [27]; however, we found
that U2OS cells expressing an APIM-YFP fusion protein are
viable and have normal growth rates (unpublished data). U2OS
cells are also tolerant to ATX-101 treatment (Figure 2A).
Thus even though our data suggests that APIM- and PIP-box-
peptides have an overlapping binding site on PCNA, their binding
to PCNA likely involves multilayered regulatory mechanisms,
including different post-translational modifications and different
affinities between and within the two PCNA-interaction motifs
(regulation of PIP-PCNA interactions reviewed in [5]), that could
partly explain the broader cytotoxicity of PIP-box peptides
compared to our APIM-peptide ATX-101. Many different cellular
functions are regulated by PCNA at different sites in the cell, e.g.
in cytosol, replication foci, and at sites of DNA repair. There is
also increasing evidence for different post-translational modifica-
tions on PCNA. During replication the PCNA molecules at the
front of the replication fork carrying the replicative polymerase
likely have either different or no post-translational modifications
than the PCNA molecules interacting with proteins involved in
arrested replication fork restart, post-replicative DNA repair, or
chromatin remodeling [12,13,26,28–31].
Importantly, ATX-101 treatment rapidly induced apoptosis in
all cell cycle phases. This is mechanistically different from two
small molecules that have recently been reported to bind PCNA
and inhibit cancer cell growth by interfering with PCNA’s function
during replication [32,33]. That ATX-101 also rapidly induced
cancer cell apoptosis in G1-phase, i.e. independent of replication,
makes it a very good candidate for further development. Many
drug candidates fail in Phase II after promising pre-clinical results
partly because their activity is dependent on a high proliferation
rate in the target cells [34]. Our data on primary MM cells, alone
and in co-culture with BMSC, together with the data in the
xenograft mouse model clearly support the pro-apoptotic cancer-
specific activity of ATX-101. Analogous to the new role of PCNA
as an inhibitor of the natural cytotoxicity receptor on natural killer
cells [9], ATX-101 may interfere with the MM cell-BMSC
interaction in addition to directly targeting the cancer cells. ATX-
101 was well tolerated in mice suggesting that there is a significant
therapeutic window.
Like most other cancers MM develops following a variety of
different genetic aberrations. Recent studies involving whole
genome sequencing in MM patients describe this heterogeneity
and even point to the existence of multiple cancer cell clones with
individual oncogenetic signatures within the same patient [14,15].
Therefore, developing a curative treatment for MM patients
would likely imply targeting several different signaling pathways
and cellular functions simultaneously. The drugs currently used
against MM have different modes of action: Thalidomide/
lenalidomide has immunomodulatory and anti-angiogenic prop-
erties, bortezomib inhibits proteasomal degradation, and melpha-
lan is a DNA damage-inducing alkylating agent. On the contrary,
ATX-101 targets PCNA’s protein interaction via APIM and thus
probably impairs several different functions such as regulation of
apoptosis, DNA repair, chromatin remodeling/epigenetic chang-
es, and regulation of several different signal transduction pathways
simultaneously [12,13]. This makes ATX-101 a promising new
compound for the treatment of MM.
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